PFS
CRSP icon

Prospera Financial Services’s CRISPR Therapeutics CRSP Stock Holding History

Prospera Financial Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Sell
3,928
-871
-18% -$45.9K ﹤0.01% 1373
2026
Q1 		$228K Buy
4,799
+74
+2% +$3.9K ﹤0.01% 1308
2025
Q4 		$248K Sell
4,725
-1,127
-19% -$67.5K ﹤0.01% 1210
2025
Q3 		$379K Sell
5,852
-246
-4% -$14.1K 0.01% 1057
2025
Q2 		$297K Buy
+6,098
New +$236K 0.01% 1108
2024
Q3 		– Sell
-3,810
Closed -$206K – 1132
2024
Q2 		$206K Sell
3,810
-408
-10% -$23.6K 0.01% 1061
2024
Q1 		$287K Buy
+4,218
New +$302K 0.01% 916
2022
Q3 		– Sell
-1,346
Closed -$82K – 997
2022
Q2 		$82K Sell
1,346
-240
-15% -$14.1K ﹤0.01% 937
2022
Q1 		$100K Buy
+1,586
New +$99.6K ﹤0.01% 1113
2020
Q4 		– Sell
-596
Closed -$50K – 845
2020
Q3 		$50K Buy
+596
New +$52.9K 0.02% 617

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prospera Financial Services's CRSP Position: Q2 2026 in Review

Prospera Financial Services reduced its CRISPR Therapeutics (CRSP) stake by 18% in Q2 2026, selling an estimated $45.9K and leaving 3,928 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

Prospera Financial Services first reported a position in CRSP in Q3 2020 and has held it in 10 quarters since. The position peaked at $379K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Prospera Financial Services held 3,928 shares of CRISPR Therapeutics worth $214K as of Q2 2026.
  • Prospera Financial Services sold 871 CRISPR Therapeutics shares in Q2 2026, an estimated $45.9K.
  • CRISPR Therapeutics made up ﹤0.01% of Prospera Financial Services's portfolio in Q2 2026, its #1373 holding.
  • Prospera Financial Services first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 10 quarters since.
  • Prospera Financial Services's CRISPR Therapeutics position peaked at $379K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Prospera Financial Services's 13F filing for Q2 2026, filed 15 Jul 2026.